Drisapersen: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{dictionary-stub2}} | {{dictionary-stub2}} | ||
{{short-articles-ni}} | {{short-articles-ni}} | ||
{{No image}} | |||
{{No image}} | |||
Latest revision as of 15:35, 10 February 2025
Drisapersen (also known as Kyndrisa, PRO051 and GSK2402968) is an experimental drug that was under development by BioMarin, after acquisition of Prosensa, for the treatment of Duchenne muscular dystrophy. The drug is a 2'-O-methyl phosphorothioate oligonucleotide that alters the splicing of the dystrophin RNA transcript, eliminating exon 51 from the mature dystrophin mRNA
| This article is a stub. You can help WikiMD by registering to expand it. |
